Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AstraZeneca PLC - American Depositary Shares
(NQ:
AZN
)
83.87
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Oct 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
425,675
Open
83.87
Bid (Size)
83.51 (6)
Ask (Size)
83.55 (4)
Prev. Close
83.87
Today's Range
83.87 - 83.87
52wk Range
61.24 - 86.57
Shares Outstanding
N/A
Dividend Yield
1.23%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
October 20, 2025
Via
Stocktwits
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
October 19, 2025
From
AstraZeneca
Via
Business Wire
Performance
YTD
+27.3%
+27.3%
1 Month
+8.2%
+8.2%
3 Month
+22.0%
+22.0%
6 Month
+25.4%
+25.4%
1 Year
+8.3%
+8.3%
More News
Read More
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
October 18, 2025
From
AstraZeneca
Via
Business Wire
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
October 18, 2025
Via
Investor's Business Daily
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump
October 10, 2025
Via
Stocktwits
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
October 18, 2025
From
AstraZeneca
Via
Business Wire
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
October 17, 2025
From
AstraZeneca
Via
Business Wire
Invo Fertility Stock Is Plunging After White House Announcement
October 17, 2025
Via
Benzinga
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
October 17, 2025
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
October 17, 2025
From
AstraZeneca
Via
Business Wire
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
October 16, 2025
Via
Benzinga
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
October 16, 2025
Via
Benzinga
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
October 16, 2025
Via
The Motley Fool
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
October 15, 2025
Via
Benzinga
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
October 15, 2025
Via
Stocktwits
AstraZeneca unveils expanded manufacturing facility in Texas
October 15, 2025
From
AstraZeneca
Via
Business Wire
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
October 15, 2025
Via
Chartmill
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
October 14, 2025
Via
Benzinga
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
October 13, 2025
Via
MarketMinute
Topics
Artificial Intelligence
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
October 13, 2025
From
AstraZeneca
Via
Business Wire
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans
October 10, 2025
Via
Benzinga
Topics
Government
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
October 10, 2025
Via
Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
October 09, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
October 09, 2025
Via
MarketMinute
Topics
Economy
Intellectual Property
Retirement
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs
October 09, 2025
Via
Benzinga
Topics
Artificial Intelligence
Frequently Asked Questions
Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 83.87
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 10/20/25 04:15 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.